Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365922 · ClinicalTrials.gov registry record
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 1,489
- Enrollment target
NCT02365922 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 1,489 participants.
The verdict
NCT02365922 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 1,489 participants
- Enrollment target
Study Summary
Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials. The consortium, referred to as Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Participants will be evaluated at 14 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,489 participants |
| Start Date | 2014-09 |
| Est. Completion | 2020-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365922
The ClinicalTrials.gov registry entry for NCT02365922 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,489 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02365922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02365922 about?
NCT02365922 is a clinical study titled "Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)". Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progr...
What is the current status of trial NCT02365922?
This trial is currently completed. The enrollment target is 1,489 participants. The study started on 2014-09. Estimated completion is 2020-09.
Who is sponsoring clinical trial NCT02365922?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.